Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc4.1 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Significant weight loss resulted in reduced levothyroxine requirements during a tesomet trial of hypopituitary patients with acquired hypothalamic obesity

Klose Marianne , Huynh Kim , Tfelt Jacob , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...

ea0070aep1073 | Hot topics (including COVID-19) | ECE2020

A randomized-controlled trial of tesomet resulted in significant weight loss in hypopituitary patients with hypothalamic obesity

Huynh Kim , Klose Marianne , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Background and objective: Hypothalamic obesity is characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic disorders. Currently, there are no approved or effective pharmacological treatments and conventional weight management remain largely ineffective in hypothalamic obesity. This trial investigated safety and efficacy of Tesomet (0.5 mg tesofensine and 50 mg metoprolol) in hypopituitary patients with hypothalamic obesity.<p class=...